The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 341-347

  Nahum, Amit ^a,b,c   Dadi, Harjit ^a,c   Bates, Andrea ^a,c   Roifman, Chaim M ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b KAPLAN MEDICAL CENTER   (Israel)

^c The Canadian Israel Immunodeficiency Research Alliance   (Canada)

Author keywords

Autoimmunity; Candidiasis; CMV; Mutation; Toll like receptors (TLR)

Indexed keywords

BETA INTERFERON; LIGAND; TOLL LIKE RECEPTOR 3;

AUTOIMMUNITY; CANDIDA ALBICANS; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; FIBROBLAST; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; MUTANT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; REVIEW; SKIN CANDIDIASIS; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNITY; CANDIDA ALBICANS; CANDIDIASIS, CUTANEOUS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MUTATION; POLY I-C; SKIN DISEASES, VIRAL; TOLL-LIKE RECEPTOR 3;

EID: 84857506024     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.10.007     Document Type: Review

References (41)

1. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19(1):24-32.
2. Zhang S.Y., Jouanguy E., Sancho-Shimizu V., von Bernuth H., Yang K., Abel L., et al. Human toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 2007, 220:225-236.
3. Bowie A.G., Haga I.R. The role of toll-like receptors in the host response to viruses. Mol Immunol 2005, 42(8):859-867.
4. Tabeta K., Georgel P., Janssen E., Du X., Hoebe K., Crozat K., et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 2004, 101(10):3516-3521.
5. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299(5615):2076-2079.
6. von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321(5889):691-696.
7. Casrouge A., Zhang S.Y., Eidenschenk C., Jouanguy E., Puel A., Yang K., et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314(5797):308-312.
8. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317(5844):1522-1527.
9. Gil M.L., Gozalbo D. Role of toll-like receptors in systemic Candida albicans infections. Front Biosci 2009, 14:570-582.
10. Netea M.G., van de Veerdonk F., Verschueren I., van der Meer J.W., Kullberg B.J. Role of TLR1 and TLR6 in the host defense against disseminated candidiasis. FEMS Immunol Med Microbiol 2008, 52(1):118-123.
11. Müller V., Viemann D., Schmidt M., Endres N., Ludwig S., Leverkus M., et al. Candida albicans triggers activation of distinct signaling pathways to establish a proinflammatory gene expression program in primary human endothelial cells. J Immunol 2007, 179(12):8435-8445.
12. Villamón E., Gozalbo D., Roig P., Murciano C., O'Connor J.E., Fradelizi D., et al. Myeloid differentiation factor 88 (MyD88) is required for murine resistance to Candida albicans and is critically involved in Candida-induced production of cytokines. Eur Cytokine Netw 2004, 15(3):263-271.
13. Gantner B.N., Simmons R.M., Underhill D.M. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J 2005, 24(6):1277-1286.
14. Kesh S., Mensah N.Y., Peterlongo P., Jaffe D., Hsu K., VAN DEN Brink M., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005, 1062:95-103.
15. Woehrle T., Du W., Goetz A., Hsu H.Y., Joos T.O., Weiss M., et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008, 41(3):322-329.
16. Van der Graaf C.A., Netea M.G., Morré S.A., Den Heijer M., Verweij P.E., Van der Meer J.W., et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006, 17(1):29-34.
17. Ferwerda B., Ferwerda G., Plantinga T.S., Willment J.A., van Spriel A.B., Venselaar H., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361(18):1760-1767.
18. Glocker E.O., Hennigs A., Nabavi M., Schäffer A.A., Woellner C., Salzer U., et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009, 361(18):1727-1735.
19. Nahum A., Bates A., Sharfe N., Roifman C.M. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008, 122(6):1220-1222.
20. Nagamine K., Peterson P., Scott H.S., Kudoh J., Minoshima S., Heino M., et al. Positional cloning of the APECED gene. Nat Genet 1997, 17:393-398.
21. Ahonen P., Myllärniemi S., Sipilä I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990, 322(26):1829-1836.
22. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312(5780):1669-1672.
23. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25(3):417-428.
24. Dogusan Z., García M., Flamez D., Alexopoulou L., Goldman M., Gysemans C., et al. Double-stranded RNA induces pancreatic beta-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways. Diabetes 2008, 57(5):1236-1245.
25. Touil T., Fitzgerald D., Zhang G.X., Rostami A., Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006, 177(11):7505-7509.
26. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413(6857):732-738.
27. Bell J.K., Botos I., Hall P.R., Askins J., Shiloach J., Davies D.R., et al. The molecular structure of the TLR3 extracellular domain. J Endotoxin Res 2006, 12(6):375-378.
28. Ranjith-Kumar C.T., Miller W., Sun J., Xiong J., Santos J., Yarbrough I., et al. Effects of single nucleotide polymorphisms on toll-like receptor 3 activity and expression in cultured cells. J Biol Chem 2007, 282(24):17696-17705.
29. Nahum A., Dadi H., Bates A., Roifman C.M. The L412F variant of TLR3 is associated with cutaneous candidiasis, increased susceptibility to CMV and autoimmunity. J Allergy Clin Immunol 2001, 127(2):528-531.
30. Sun Y., Leaman D.W. Ectopic expression of toll-like receptor-3 (TLR-3) overcomes the double-stranded RNA (dsRNA) signaling defects of P2.1 cells. J Interferon Cytokine Res 2004, 24(6):350-361.
31. Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A 1997, 94(7):3168-3171.
32. Dhiman N., Ovsyannikova I.G., Vierkant R.A., Ryan J.E., Pankratz V.S., Jacobson R.M., et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008, 26(14):1731-1736.
33. Ishizaki Y., Takemoto M., Kira R., Kusuhara K., Torisu H., Sakai Y., et al. Association of toll-like receptor 3 gene polymorphism with subacute sclerosing panencephalitis. J Neurovirol 2008, 14(6):486-491.
34. Hervas-Stubbs S., Olivier A., Boisgerault F., Thieblemont N., Leclerc C. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 2007, 109(12):5318-5326.
35. Gelman A.E., Zhang J., Choi Y., Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004, 172(10):6065-6073.
36. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4(1):69-77.
37. Uze G., Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89(6-7):729-734.
38. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75(2):163-189.
39. Netea M.G., Van Der Graaf C.A., Vonk A.G., Verschueren I., Van Der Meer J.W., Kullberg B.J. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002, 185(10):1483-1489.
40. Gozalbo D., Gil M.L. IFN-gamma in Candida albicans infections. Front Biosci 2009, 14:1970-1978.
41. Yang Z., Stratton C., Francis P.J., Kleinman M.E., Tan P.L., Gibbs D., et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008, 359(14):1456-1463.